ÓижøȾ 2024Äê09ÔÂ17ÈÕ 23:58 ºÓ±±
2024Äê8Ô£¬£¬£¬ £¬ £¬£¬ÖÐÄÏ´óѧÏæÑÅÈýҽԺлÔÃÁ¼½ÌÊÚÔÚJournal of Antimicrobial Chemotherapy£¨2024ÄêIF3.9£©½ÒÏþÁË¡°Õ¹Íû¶àð¤¾úËØÓÕµ¼Éö¶¾ÐÔµÄÊÔµãÁÙ´²Î£º¦Ä£×Ó£ºÒ»ÏîÕæʵÌìÏ»ØÊ×ÐÔÐÐÁÐÑо¿¡±£¬£¬£¬ £¬ £¬£¬ÌâΪA pilot clinical risk model to predict polymyxin-induced nephrotoxicity: a real-world, retrospective cohort study¡£¡£¡£¡£
Ä¿µÄ£º¶àð¤¾úËØÓÕµ¼µÄÉö¶¾ÐÔ £¨PIN£© ÊÇÁÙ´²Êµ¼ùÖеÄÖ÷ÒªÇå¾²ÎÊÌâºÍÌôÕ½£¬£¬£¬ £¬ £¬£¬ÏÞÖÆÁ˶àð¤¾úËصÄÁÙ´²Ó¦Óᣡ£¡£¡£±¾Ñо¿Ö¼ÔÚÊÓ²ìΣº¦ÒòËز¢¿ª·¢Ò»ÖÖÓÃÓÚ PIN ÔçÆÚÕ¹ÍûµÄÆÀ·Ö¹¤¾ß¡£¡£¡£¡£ÒªÁì:ÍøÂç¾²Âö×¢Éä¶àð¤¾úËØB»òÁòËáð¤¾úËØÁè¼Ý24 hµÄΣÖØ»¼Õß×ÊÁÏ¡£¡£¡£¡£Ê¹ÓÃ×îС¾ø¶ÔËõ¶ÌºÍÑ¡ÔñËã×Ó(LASSO)µÄÂß¼»Ø¹éÀ´Ê¶±ðÓëЧ¹ûÏà¹ØµÄ±äÁ¿¡£¡£¡£¡£½ÓÄɼ«ÏÞÌݶÈÔöÇ¿(eXtreme Gradient Boosting, XGB)·ÖÀàÆ÷Ëã·¨¶Ô²î±ðÏÔÖøµÄÒò×Ó¾ÙÐнøÒ»²½¿ÉÊÓ»¯¡£¡£¡£¡£Í¨¹ý¶þÔªlogistic»Ø¹éÆÊÎö½¨ÉèPINÕ¹ÍûÄ£×Ó£¬£¬£¬ £¬ £¬£¬²¢¶ÔÄ£×Ó¾ÙÐÐʱ¼äÑéÖ¤ºÍÍⲿÑéÖ¤¡£¡£¡£¡£×îºó£¬£¬£¬ £¬ £¬£¬½¨ÉèÁË»ùÓÚÕ¹ÍûÄ£×ÓµÄΣº¦ÆÀ·Öϵͳ¡£¡£¡£¡£Ð§¹û:508Àý»¼ÕßÖУ¬£¬£¬ £¬ £¬£¬161Àý(31.6%)±¬·¢PIN¡£¡£¡£¡£¶àð¤¾úËØÀàÐÍ¡¢¸ººÉ¼ÁÁ¿¡¢Ñ¬È¾ÐÔÐÝ¿Ë¡¢ºÏ²¢Ñª¹Ü¼ÓѹҩÎïºÍ»ùÏßѪÄòËصª(BUN)ˮƽ±»ÒÔΪÊÇPINµÄÏÔÖøÕ¹ÍûÒòËØ¡£¡£¡£¡£ËùÓÐÑéÖ¤¶¼ÌåÏÖ³öºÜ´óµÄÅбðÐÔ£¬£¬£¬ £¬ £¬£¬ÄÚ²¿ÑéÖ¤µÄAUCΪ0.742 (95% CI: 0.696-0.787)£¬£¬£¬ £¬ £¬£¬Ê±¼äÑéÖ¤µÄAUCΪ0.708 (95% CI: 0.605-0.810)£¬£¬£¬ £¬ £¬£¬ÍⲿÑéÖ¤µÄAUCΪ0.874 (95% CI: 0.759-0.989)¡£¡£¡£¡£¿£¿ª·¢ÁËÒ»ÖÖ¼òÆÓµÄΣº¦ÆÀ·Ö¹¤¾ß£¬£¬£¬ £¬ £¬£¬×ÜΣº¦ÆÀ·Ö¹æģΪ-3 ~ 4£¬£¬£¬ £¬ £¬£¬¶ÔÓ¦PINµÄΣº¦¹æģΪ0.79% ~ 81.24%¡£¡£¡£¡£ÔÚ¸ÃÑо¿ÖУ¬£¬£¬ £¬ £¬£¬ÁòËáð¤¾úËØ×é143Àý£¬£¬£¬ £¬ £¬£¬ÆäÖÐ31Àý±¬·¢AKI£¬£¬£¬ £¬ £¬£¬ÁòËá¶àð¤¾úËØB×é334Àý£¬£¬£¬ £¬ £¬£¬ÆäÖÐ130Àý±¬·¢AKI¡£¡£¡£¡£ÁòËáð¤¾úËØ VS ÁòËá¶àð¤¾úËØBÓÕµ¼AKIµÄ±ÈÀýΪ17.8% vs 38.9%£¬£¬£¬ £¬ £¬£¬P£¼0.001¡£¡£¡£¡£ÇãÏòÆ¥Åä¶ÓÁк󣬣¬£¬ £¬ £¬£¬ÁòËáð¤¾úËØ VS ÁòËá¶àð¤¾úËØBÓÕµ¼AKIµÄ±ÈÀýΪ17.8% vs 40.8%£¬£¬£¬ £¬ £¬£¬P£¼0.001¡£¡£¡£¡£
×ÉѯÈÈÏß
